TRON is located at the Technologiezentrum Mainz. Our focus is translating scientific insight into clinical practice and developing them for commercialization. TRON’s forward-looking organizational structure was designed to integrate ideas, cutting-edge technologies and expertise in genomics and next-generation sequencing, bioinformatics and biostatistics, immunology, immunotherapy, and molecular biology. TRON is also a hub in the Rhein-Main region, coordinating and accelerating drug and diagnostics research projects in the public-private interface.
TRON’s research budget is expected to exceed 30 million € over the first 5 years. The state of Rhineland-Palatinate is providing approximately one-third of the sum, while the remainder will be financed by project-specific funding from governmental sources and industry collaborations.
Within TRON two main research departments each address a main contemporary demand in individualized medicine. The Biomarker Development Center (BDC) researches and validates clinically relevant molecular, cellular, and serological biomarkers, while the Immunotherapy Development Center (IDC) develops immunotherapy approaches, including monoclonal antibodies, recombinant vaccines, adoptive cellular therapies and gene therapies. The two departments share technology units and labs which have been equipped with the most advanced technology platforms and which provide quality controlled services.
We pursue the following main objectives:
- Cutting-edge research in the field of oncology and immunology with a focus on cancer genomics, cancer immune recognition and immunotherapy.
- Active technology transfer of our own innovations and those of other academic research groups, including further development, validation of research results and evaluation of an idea’s or patent’s potential for commercialization. A number of our patents have already been licensed to industry and are currently undergoing product development.
- Collaboration with biotechnology and pharmaceutical companies in research projects or in the provision of highly specialized research services to advance product development in the private sector. TRON has a diverse range of cutting-edge core facility services available and a broad portfolio of technologies optimized for use with clinical blood samples and tissue sections, including paraffin-embedded specimens. Our analysis of biological samples includes next-generation sequencing, immunoprofiling assays for measuring human and mouse CD8+ CD4+ T cells, including multicolor-flow cytometry, ELISPOT, peptide microarrays, non-radioactive cytotoxicity and proliferation assays and peptide microarrays for broad spectrum autoantibody profiling. Our technology portfolio and services are outlined in more detail under TRON Facilities.
- Education, training and qualification of students, scientists and medical doctors specializing in cancer research, immunology and all aspects of translational research. For more information about our research projects, please see the menu item Research.